Navitas stock soars as company advances 800V tech for NVIDIA AI platforms
Natera, Inc. (NASDAQ:NTRA), currently valued at $24.9 billion, saw its Executive Chairman Matthew Rabinowitz sell shares of the company’s common stock worth approximately $9.02 million, according to a new SEC filing. The sale comes as InvestingPro data shows the stock trading near its 52-week high of $183, with a strong 41.7% return over the past year. The sales occurred in multiple transactions between September 18 and September 19, 2025, with prices ranging from $180.0 to $181.282 per share.
On September 18, Rabinowitz sold 10,000 shares indirectly at a price of $180 per share. On the same day, he also sold 14,473 shares directly, at a weighted average price of $180.1333, in a range of $180.00 to $180.37. On September 19, he sold 24,339 shares directly at a weighted average price of $180.5430, in a range of $180.00 to $180.99, and 1,188 shares directly at a weighted average price of $181.2820, in a range of $181.00 to $181.40.
Following these transactions, Rabinowitz directly owns 2,320,852 shares of Natera, Inc. common stock. The sales were executed pursuant to Rule 10b5-1 trading plans adopted on March 14, 2025 and June 13, 2025. For comprehensive insider trading analysis and 13 additional key insights about NTRA, visit InvestingPro.
In other recent news, Natera has reported positive results from its Phase III IMvigor011 clinical trial, which demonstrated significant advancements in Minimal Residual Disease (MRD) testing. This trial, sponsored by Genentech, showed that patients with a negative MRD status experienced improved overall survival rates, an important outcome in oncology. In response to these positive results, UBS reiterated its Buy rating with a price target of $218.00 for Natera. Additionally, Piper Sandler maintained an Overweight rating and set a price target of $220.00, highlighting the clinical trial’s success as a significant development.
RBC Capital also raised its price target for Natera to $255.00 from $251.00, citing another strong quarter for the company. However, Natera faced a setback when a North Carolina district court invalidated its patent claims in a dispute with NeoGenomics, ruling that the claims involved ineligible subject matter. Despite this legal challenge, Natera is moving forward with its premarket approval application to the FDA for its Signatera test as a companion diagnostic tool. These developments underscore Natera’s ongoing efforts in advancing its medical testing technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.